lamivudine has been researched along with mycophenolic acid in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (76.92) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ben-Ari, Z; Tur-Kaspa, R; Zemel, R | 1 |
| Chiu, MC; Lai, WM; Lau, SC; Tse, KC | 1 |
| Back, DJ; Beijnen, JH; Crommentuyn, KM; Hoggard, PG; Huitema, AD; Kewn, S; Lange, JM; Prins, JM; Sankatsing, SU; Sparidans, RW | 1 |
| Colonno, R; De Clercq, E; Neyts, J; Ying, C | 1 |
| Chang, HR; Lian, JD; Lin, CC | 1 |
| Janković, S; Marović, A; Matijaca, M; Pintarić, I; Vlasić-Matas, J | 1 |
| Lu, AW; Shen, Y; Wu, MP; Yang, RW; Zheng, SS | 1 |
| Booth, J; Chowdary, P; Khurram, MA; Mohamed, IH; Shetty, S; Yaqoob, M | 1 |
2 review(s) available for lamivudine and mycophenolic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Experience of SARS-CoV-2 infection in two kidney transplant recipients living with HIV-1 infection.
Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Atovaquone; CD4 Lymphocyte Count; CD4-CD8 Ratio; COVID-19; Dideoxynucleosides; Female; Glucocorticoids; Graft Rejection; HIV Infections; HIV-1; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Male; Middle Aged; Mycophenolic Acid; Pneumonia, Pneumocystis; Prednisolone; Raltegravir Potassium; RNA, Viral; SARS-CoV-2; Tacrolimus; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |
2 trial(s) available for lamivudine and mycophenolic acid
| Article | Year |
|---|---|
Use of prophylactic lamivudine and mycophenolate mofetil in renal transplant recipients with chronic hepatitis B infection.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibiotic Prophylaxis; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lamivudine; Male; Mycophenolic Acid; Treatment Outcome | 2003 |
Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Retroviral Agents; Cytidine Triphosphate; Deoxycytosine Nucleotides; Deoxyguanine Nucleotides; Dideoxynucleotides; Drug Interactions; HIV-1; Humans; Lamivudine; Male; Metabolic Clearance Rate; Middle Aged; Mycophenolic Acid | 2004 |
9 other study(ies) available for lamivudine and mycophenolic acid
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
The addition of mycophenolate mofetil for suppressing hepatitis B virus replication in liver recipients who developed lamivudine resistance--no beneficial effect.
Topics: Adult; Antiviral Agents; Drug Resistance, Microbial; Female; Hepatitis B virus; Humans; Immunosuppressive Agents; Lamivudine; Liver Transplantation; Male; Middle Aged; Mycophenolic Acid; Virus Replication | 2001 |
Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir.
Topics: Cell Line; DNA-Directed DNA Polymerase; DNA, Viral; Drug Synergism; Drug Therapy, Combination; Guanine; Hepacivirus; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Mycophenolic Acid; Ribavirin; RNA-Directed DNA Polymerase | 2007 |
Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients.
Topics: Adult; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis C; Histocompatibility Testing; Humans; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Liver; Male; Middle Aged; Monitoring, Immunologic; Mycophenolic Acid; Retrospective Studies; Sirolimus; Tacrolimus | 2007 |
Neurotoxicity that may mimic progressive multifocal leukoencephalopathy in patient with transplanted kidney.
Topics: Cyclosporine; Female; Humans; Kidney Transplantation; Lamivudine; Leukoencephalopathy, Progressive Multifocal; Middle Aged; Mycophenolic Acid; Neurotoxicity Syndromes | 2007 |
Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation.
Topics: DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Glucocorticoids; Hepatitis B; Hepatitis B Antibodies; Hepatitis B virus; Humans; Immunoglobulins; Immunosuppressive Agents; Lamivudine; Liver Transplantation; Mutation; Mycophenolic Acid; Odds Ratio; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Assessment; Secondary Prevention; Time Factors; Treatment Outcome | 2008 |